Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J. Skouby SO, et al. Among authors: dusterberg b. Contraception. 2005 Feb;71(2):111-7. doi: 10.1016/j.contraception.2004.08.017. Contraception. 2005. PMID: 15707560 Clinical Trial.
A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
Endrikat J, Jaques MA, Mayerhofer M, Pelissier C, Müller U, Düsterberg B. Endrikat J, et al. Among authors: dusterberg b. Contraception. 1995 Oct;52(4):229-35. doi: 10.1016/0010-7824(95)00191-c. Contraception. 1995. PMID: 8605781 Clinical Trial.
A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J, Müller U, Düsterberg B. Endrikat J, et al. Among authors: dusterberg b. Contraception. 1997 Mar;55(3):131-7. doi: 10.1016/s0010-7824(97)00025-5. Contraception. 1997. PMID: 9115000 Clinical Trial.
Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Düsterberg B. Endrikat J, et al. Among authors: dusterberg b. Contraception. 2001 Sep;64(3):201-7. doi: 10.1016/s0010-7824(01)00235-9. Contraception. 2001. PMID: 11704101 Clinical Trial.
A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism.
Endrikat J, Klipping C, Gerlinger C, Ruebig A, Schmidt W, Holler T, Düsterberg B. Endrikat J, et al. Among authors: dusterberg b. Contraception. 2001 Oct;64(4):235-41. doi: 10.1016/s0010-7824(01)00236-0. Contraception. 2001. PMID: 11747873 Clinical Trial.
44 results